BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
48 hedge funds and large institutions have $20.4M invested in BRAINSTORM CELL THERAPUTC in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 5 closing their positions.
232% more capital invested
Capital invested by funds: $6.16M → $20.4M (+$14.3M)
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
12% more funds holding
Funds holding: 43 → 48 (+5)
0.49% more ownership
Funds ownership: 0.67% → 1.16% (+0.49%)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
21% less call options, than puts
Call options by funds: $1.08M | Put options by funds: $1.37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$2.82M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$694K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$572K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$333K |
| 5 |
CSC
Caldwell Sutter Capital
Sausalito,
California
|
+$304K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
-$139K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$92.8K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$61.6K |
| 4 |
Millennium Management
New York
|
-$58.8K |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$33K |
BCLI Hedge Fund Activity: Q1 2023 in Review
48 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q1 2023, worth a combined $20.4M — up 232% from $6.16M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new BCLI positions and 5 closed out — a net gain of 7 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $2.82M. The largest seller was IFP Advisors, exiting entirely with an estimated $139K sold.
- 48 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q1 2023, up from 43 in Q4 2022.
- Funds reported $20.4M of BRAINSTORM CELL THERAPUTC stock for Q1 2023, up 232% quarter-over-quarter.
- 12 funds opened new BRAINSTORM CELL THERAPUTC positions in Q1 2023 and 5 closed out, a net change of +7 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q1 2023 was AIGH Capital Management, an estimated $2.82M added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q1 2023 was IFP Advisors, an estimated $139K sold.
Based on aggregated 13F filings for Q1 2023.